CellSeed Inc. (7776.T)
JPY 583.0
(-4.74%)
JPY 583.0
(-4.74%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.46 Billion JPY | 59.71% |
| 2022 | 1.54 Billion JPY | 9.64% |
| 2021 | 1.4 Billion JPY | -22.05% |
| 2020 | 1.8 Billion JPY | 24.07% |
| 2019 | 1.45 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 2.42 Billion JPY | 2.27% |
| 2024 Q1 | 2.37 Billion JPY | -3.73% |
| 2023 Q2 | 2.04 Billion JPY | 0.78% |
| 2023 Q4 | 2.46 Billion JPY | -6.62% |
| 2023 Q1 | 2.02 Billion JPY | 31.43% |
| 2023 FY | 2.46 Billion JPY | 59.71% |
| 2023 Q3 | 2.64 Billion JPY | 29.12% |
| 2022 Q3 | 1.48 Billion JPY | 0.0% |
| 2022 FY | 1.54 Billion JPY | 9.64% |
| 2022 Q4 | 1.54 Billion JPY | 4.14% |
| 2021 FY | 1.4 Billion JPY | -22.05% |
| 2020 FY | 1.8 Billion JPY | 24.07% |
| 2019 FY | - JPY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | 62.579% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -103.543% |
| GNI Group Ltd. | 62.39 Billion JPY | 96.048% |
| Linical Co., Ltd. | 18.53 Billion JPY | 86.7% |
| Trans Genic Inc. | 9.81 Billion JPY | 74.867% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | 56.235% |
| Soiken Holdings Inc. | 6.94 Billion JPY | 64.502% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | 57.606% |
| AnGes, Inc. | 28.89 Billion JPY | 91.466% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -184.312% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 98.431% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -52.341% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | 51.378% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | 43.314% |
| CanBas Co., Ltd. | 2.43 Billion JPY | -1.353% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | -3.893% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | 64.42% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -40.784% |
| Kidswell Bio Corporation | 5.08 Billion JPY | 51.514% |
| PeptiDream Inc. | 67.12 Billion JPY | 96.327% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -20.836% |
| Ribomic Inc. | 3.54 Billion JPY | 30.488% |
| SanBio Company Limited | 5.04 Billion JPY | 51.147% |
| Healios K.K. | 15.15 Billion JPY | 83.73% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -100.427% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | 18.244% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -67.267% |
| StemRIM | 9.08 Billion JPY | 72.844% |
| CellSource Co., Ltd. | 6.87 Billion JPY | 64.159% |
| FunPep Company Limited | 2.49 Billion JPY | 1.018% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | 5.838% |
| Stella Pharma Corporation | 3.82 Billion JPY | 35.462% |
| TMS Co., Ltd. | 3.55 Billion JPY | 30.635% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | 57.332% |
| Cuorips Inc. | 6.18 Billion JPY | 60.131% |
| K Pharma,Inc. | 3.31 Billion JPY | 25.593% |
| Takara Bio Inc. | 123.2 Billion JPY | 97.999% |
| ReproCELL Incorporated | 9.05 Billion JPY | 72.762% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | 9.191% |
| StemCell Institute Inc. | 6.54 Billion JPY | 62.315% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 64.718% |